JP2018510650A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018510650A5 JP2018510650A5 JP2017560883A JP2017560883A JP2018510650A5 JP 2018510650 A5 JP2018510650 A5 JP 2018510650A5 JP 2017560883 A JP2017560883 A JP 2017560883A JP 2017560883 A JP2017560883 A JP 2017560883A JP 2018510650 A5 JP2018510650 A5 JP 2018510650A5
- Authority
- JP
- Japan
- Prior art keywords
- cmv
- cells
- cmv vector
- vector
- tcr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020213267A JP2021121185A (ja) | 2015-02-10 | 2020-12-23 | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 |
| JP2022126096A JP2022166122A (ja) | 2015-02-10 | 2022-08-08 | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562114203P | 2015-02-10 | 2015-02-10 | |
| US62/114,203 | 2015-02-10 | ||
| US201562196520P | 2015-07-24 | 2015-07-24 | |
| US62/196,520 | 2015-07-24 | ||
| US201562220703P | 2015-09-18 | 2015-09-18 | |
| US62/220,703 | 2015-09-18 | ||
| PCT/US2016/017373 WO2016130693A1 (en) | 2015-02-10 | 2016-02-10 | Methods and compositions useful in generating non canonical cd8+ t cell responses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020213267A Division JP2021121185A (ja) | 2015-02-10 | 2020-12-23 | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018510650A JP2018510650A (ja) | 2018-04-19 |
| JP2018510650A5 true JP2018510650A5 (enExample) | 2019-03-22 |
| JP6816031B2 JP6816031B2 (ja) | 2021-01-20 |
Family
ID=56615684
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017560883A Expired - Fee Related JP6816031B2 (ja) | 2015-02-10 | 2016-02-10 | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 |
| JP2020213267A Pending JP2021121185A (ja) | 2015-02-10 | 2020-12-23 | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 |
| JP2022126096A Pending JP2022166122A (ja) | 2015-02-10 | 2022-08-08 | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020213267A Pending JP2021121185A (ja) | 2015-02-10 | 2020-12-23 | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 |
| JP2022126096A Pending JP2022166122A (ja) | 2015-02-10 | 2022-08-08 | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20180298404A1 (enExample) |
| EP (2) | EP3256595A4 (enExample) |
| JP (3) | JP6816031B2 (enExample) |
| KR (1) | KR20170136512A (enExample) |
| CN (2) | CN114317611A (enExample) |
| AU (1) | AU2016219317A1 (enExample) |
| BR (1) | BR112017017092A2 (enExample) |
| CA (1) | CA2976245A1 (enExample) |
| EA (1) | EA201791806A1 (enExample) |
| HK (2) | HK1254041A1 (enExample) |
| IL (1) | IL253935B (enExample) |
| MA (1) | MA41756A (enExample) |
| MX (1) | MX2017010027A (enExample) |
| SG (1) | SG11201706454VA (enExample) |
| WO (1) | WO2016130693A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3351636T (pt) | 2010-05-14 | 2020-09-24 | Univ Oregon Health & Science | Vectores de hcmv e rhcmv recombinantes codificadores de um antigénio heterólogo isolado a partir de um vírus paramyxoviridae e seus usos |
| ES2667425T3 (es) | 2011-06-10 | 2018-05-10 | Oregon Health & Science University | Glucoproteínas y vectores recombinantes de CMV |
| CA2879577C (en) * | 2012-07-27 | 2021-08-03 | City Of Hope | An mva vaccine for delivery of a ul128 complex and preventing cmv infection |
| LT2964769T (lt) | 2013-03-05 | 2018-12-10 | Oregon Health & Science University | Citomegalo viruso vektoriai, leidžiantys kontroliuoti ląstelių nukreipimą į taikinį |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| NZ728208A (en) | 2014-07-16 | 2018-07-27 | Univ Oregon Health & Science | Human cytomegalovirus comprising exogenous antigens |
| EA201791806A1 (ru) | 2015-02-10 | 2017-12-29 | Орегон Хелс Энд Сайенс Юниверсити | Способы и композиции, полезные при генерировании неканонических cd8+ т-клеточных ответов |
| EP3364981A4 (en) | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
| US10688164B2 (en) | 2015-11-20 | 2020-06-23 | Oregon Health & Science University | CMV vectors comprising microRNA recognition elements |
| US20200182884A1 (en) | 2016-06-27 | 2020-06-11 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
| WO2018075591A1 (en) | 2016-10-18 | 2018-04-26 | Oregon Health & Science University | Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules |
| EP3528821A4 (en) | 2016-10-21 | 2020-07-01 | ModernaTX, Inc. | HUMAN CYTOMEGALOVIRUS VACCINE |
| EP3539552A1 (en) * | 2018-03-16 | 2019-09-18 | Deutsches Rheuma-Forschungszentrum Berlin | Activation and expansion of nkg2c+ nk cells |
| MX2021002702A (es) * | 2018-09-10 | 2021-05-12 | Atara Biotherapeutics Inc | Metodos para expandir celulas t del receptor de antigeno quimerico especificas de antigenos, composiciones y usos relacionados con las mismas. |
| US11077185B2 (en) | 2019-03-21 | 2021-08-03 | 21C Bio | Vaccine to pathogenic immune activation cells during infections |
| US10632186B1 (en) | 2019-03-21 | 2020-04-28 | 21C Bio | Vaccine to pathogenic immune activation cells during infections |
| WO2020188111A1 (en) * | 2019-03-21 | 2020-09-24 | 21C Bio | Vaccine to pathogenic immune activation cells during infections |
| CN110055228B (zh) * | 2019-04-17 | 2023-04-28 | 华中科技大学同济医学院附属协和医院 | 用于乙肝病毒感染的重组巨细胞病毒与应用 |
| WO2020247859A2 (en) * | 2019-06-07 | 2020-12-10 | Oregon Health & Science University | Tumor-associated antigen-specific t cell responses |
| CA3148642A1 (en) * | 2019-08-20 | 2021-02-25 | Klaus J. FRUEH | Modulation of t cell responses by ul18 of human cytomegalovirus |
| BR112022003474A2 (pt) | 2019-08-29 | 2022-05-24 | Triad Nat Security Llc | Vacinas do vírus da hepatite b |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| US20240384296A1 (en) | 2021-08-31 | 2024-11-21 | Vir Biotechnology, Inc. | Recombinant hcmv vectors and uses thereof |
| KR20240049802A (ko) | 2021-08-31 | 2024-04-17 | 비르 바이오테크놀로지, 인코포레이티드 | 결핵 백신 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| CA1327171C (en) | 1987-06-26 | 1994-02-22 | Lisa J. Hock | Recombinant human cytomegalovirus containing foreign gene and use thereof |
| US5273876A (en) | 1987-06-26 | 1993-12-28 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene |
| SG49046A1 (en) | 1991-07-05 | 1998-05-18 | American Cyanamid Co | Method for identifying non-essential genes of the human cytomegalovirus genome and for screening for inhibitors of human cytomegaloverirus |
| WO1995003399A2 (en) | 1993-07-19 | 1995-02-02 | Cantab Pharmaceuticals Research Limited | Production method for preparation of disabled viruses |
| US5833993A (en) | 1994-04-29 | 1998-11-10 | Pharmacia & Upjohn Company | Feline immunodeficiency virus vaccine |
| US5846806A (en) | 1994-07-29 | 1998-12-08 | American Cyanamid Company | Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression |
| ES2264136T3 (es) | 1995-02-21 | 2006-12-16 | Cantab Pharmaceuticals Research Limited | Preparaciones virales, vectores, inmunogenos y sus vacunas. |
| WO1996031241A1 (en) | 1995-04-04 | 1996-10-10 | Cell Genesys, Inc. | Transplantation of genetically modified cells having low levels of class i mhc proteins on the cell surface |
| WO1998004285A1 (en) | 1996-07-31 | 1998-02-05 | Ortho Pharmaceutical Corporation | Identification of human cytomegalovirus genes involved in down-regulation of mhc class i heavy chain expression |
| US20030138454A1 (en) | 1997-06-09 | 2003-07-24 | Oxxon Pharmaccines, Ltd. | Vaccination method |
| DE19733364A1 (de) | 1997-08-01 | 1999-02-04 | Koszinowski Ulrich H Prof | Verfahren zur Klonierung eines großen Virusgenoms |
| WO1999007869A1 (en) | 1997-08-05 | 1999-02-18 | University Of Florida | Live recombinant vaccine comprising inefficiently or non-replicating virus |
| US7204990B1 (en) | 2000-11-28 | 2007-04-17 | Medimmune Vaccines, Inc. | Attenuation of cytomegalovirus virulence |
| CA2437201C (en) | 2001-02-02 | 2008-11-18 | Chemocentryx, Inc. | Methods and compositions useful for stimulating an immune response |
| WO2002066629A2 (en) | 2001-02-21 | 2002-08-29 | Gabriele Hahn | Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates |
| GB0122232D0 (en) | 2001-09-14 | 2001-11-07 | Medical Res Council | Gene expression |
| JP4601956B2 (ja) | 2001-09-20 | 2010-12-22 | グラクソ グループ リミテッド | Ｈｉｖ−ｇａｇのコドン最適化ｄｎａワクチン |
| US20030118568A1 (en) | 2001-12-18 | 2003-06-26 | Board Of Trustees Of The University Of Arkansas | Viral stealth technology to prevent T cell-mediated rejection of xenografts |
| EP1497412A4 (en) | 2002-04-30 | 2006-11-22 | Avior Therapeutics Inc | ADENOVIRUS VECTORS USED IN IMMUNOTHERAPY |
| DE10232322A1 (de) | 2002-07-16 | 2004-07-29 | Hahn, Gabriele, Dr. | Viral kodierte CxC determinieren den Gewebetropismus von HCMV |
| US7407744B2 (en) | 2003-07-25 | 2008-08-05 | The Regents Of The University Of California | Cytomegalovirus gene function and methods for developing antivirals, anti-CMV vaccines, and CMV-based vectors |
| AU2005285513B2 (en) | 2004-05-25 | 2011-02-24 | Oregon Health And Science University | SIV and HIV vaccination using RhCMV- and HCMV-based vaccine vectors |
| EP1602676A1 (en) | 2004-06-01 | 2005-12-07 | SOLVAY (Société Anonyme) | Catalytic compositions |
| WO2006004661A1 (en) | 2004-06-25 | 2006-01-12 | Medimmune Vaccines, Inc. | Recombinant human cytomegalovirus and vaccines comprising heterologous antigens |
| WO2006125983A1 (en) | 2005-05-23 | 2006-11-30 | Oxxon Therapeutics Ltd | Compositions for inducing an immune response against hepatitis b |
| US8765146B2 (en) | 2005-08-31 | 2014-07-01 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
| WO2008112146A2 (en) | 2007-03-07 | 2008-09-18 | The Trustees Of The University Of Pennsylvania | 2d partially parallel imaging with k-space surrounding neighbors based data reconstruction |
| US8883995B2 (en) | 2009-03-06 | 2014-11-11 | Icahn School Of Medicine At Mount Sinai | Live attenuated influenza virus vaccines comprising microRNA response elements |
| AU2010334809C1 (en) | 2009-12-23 | 2015-02-26 | Agenus Inc. | Binding members for human cytomegalovirus |
| US20120289760A1 (en) | 2010-01-27 | 2012-11-15 | Hill Ann B | Cytomegalovirus-based immunogenic preparations |
| WO2011119920A2 (en) | 2010-03-25 | 2011-09-29 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| JP2013527758A (ja) | 2010-05-05 | 2013-07-04 | ティリオン，クリスティアン | ベータヘルペスウイルス感染に対するワクチンおよびその使用 |
| PT3351636T (pt) * | 2010-05-14 | 2020-09-24 | Univ Oregon Health & Science | Vectores de hcmv e rhcmv recombinantes codificadores de um antigénio heterólogo isolado a partir de um vírus paramyxoviridae e seus usos |
| ES2667425T3 (es) | 2011-06-10 | 2018-05-10 | Oregon Health & Science University | Glucoproteínas y vectores recombinantes de CMV |
| LT2964769T (lt) | 2013-03-05 | 2018-12-10 | Oregon Health & Science University | Citomegalo viruso vektoriai, leidžiantys kontroliuoti ląstelių nukreipimą į taikinį |
| NZ728208A (en) | 2014-07-16 | 2018-07-27 | Univ Oregon Health & Science | Human cytomegalovirus comprising exogenous antigens |
| EP3048114A1 (en) | 2015-01-22 | 2016-07-27 | Novartis AG | Cytomegalovirus antigens and uses thereof |
| EA201791806A1 (ru) | 2015-02-10 | 2017-12-29 | Орегон Хелс Энд Сайенс Юниверсити | Способы и композиции, полезные при генерировании неканонических cd8+ т-клеточных ответов |
| US10688164B2 (en) | 2015-11-20 | 2020-06-23 | Oregon Health & Science University | CMV vectors comprising microRNA recognition elements |
| AU2017280065B2 (en) | 2016-06-22 | 2021-07-01 | International Aids Vaccine Initiative, Inc. | Recombinant cytomegalovirus vectors as vaccines for tuberculosis |
| US20200182884A1 (en) | 2016-06-27 | 2020-06-11 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
| WO2018075591A1 (en) | 2016-10-18 | 2018-04-26 | Oregon Health & Science University | Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules |
-
2016
- 2016-02-10 EA EA201791806A patent/EA201791806A1/ru unknown
- 2016-02-10 JP JP2017560883A patent/JP6816031B2/ja not_active Expired - Fee Related
- 2016-02-10 MA MA041756A patent/MA41756A/fr unknown
- 2016-02-10 BR BR112017017092A patent/BR112017017092A2/pt not_active Application Discontinuation
- 2016-02-10 AU AU2016219317A patent/AU2016219317A1/en not_active Abandoned
- 2016-02-10 CN CN202111437865.0A patent/CN114317611A/zh active Pending
- 2016-02-10 HK HK18113013.6A patent/HK1254041A1/zh unknown
- 2016-02-10 WO PCT/US2016/017373 patent/WO2016130693A1/en not_active Ceased
- 2016-02-10 EP EP16749813.8A patent/EP3256595A4/en not_active Withdrawn
- 2016-02-10 SG SG11201706454VA patent/SG11201706454VA/en unknown
- 2016-02-10 CN CN201680014682.9A patent/CN108064304A/zh active Pending
- 2016-02-10 EP EP21205026.4A patent/EP4036239A1/en not_active Withdrawn
- 2016-02-10 HK HK18106974.7A patent/HK1247638A1/zh unknown
- 2016-02-10 MX MX2017010027A patent/MX2017010027A/es unknown
- 2016-02-10 US US15/549,814 patent/US20180298404A1/en not_active Abandoned
- 2016-02-10 CA CA2976245A patent/CA2976245A1/en not_active Abandoned
- 2016-02-10 KR KR1020177025544A patent/KR20170136512A/ko not_active Ceased
-
2017
- 2017-08-09 IL IL253935A patent/IL253935B/en unknown
-
2020
- 2020-01-09 US US16/738,178 patent/US11091779B2/en not_active Expired - Fee Related
- 2020-12-23 JP JP2020213267A patent/JP2021121185A/ja active Pending
-
2022
- 2022-08-08 JP JP2022126096A patent/JP2022166122A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Humphreys et al. | Novel viral vectors in infectious diseases | |
| O’Hara et al. | Memory T cell inflation: understanding cause and effect | |
| Khanna et al. | Human cytomegalovirus vaccine: time to look for alternative options | |
| Cohen | Vaccine development for Epstein-Barr virus | |
| Schleiss et al. | Progress toward development of a vaccine against congenital cytomegalovirus infection | |
| van Zyl et al. | Immunogenic particles with a broad antigenic spectrum stimulate cytolytic T cells and offer increased protection against EBV infection ex vivo and in mice | |
| Sung et al. | Update on the current status of cytomegalovirus vaccines | |
| Hanley et al. | Controlling cytomegalovirus: helping the immune system take the lead | |
| JP6816031B2 (ja) | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 | |
| King et al. | A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance | |
| Griffiths et al. | Desirability and feasibility of a vaccine against cytomegalovirus | |
| Ruiss et al. | A virus-like particle-based Epstein-Barr virus vaccine | |
| Farrington et al. | Competition for antigen at the level of the APC is a major determinant of immunodominance during memory inflation in murine cytomegalovirus infection | |
| JP2023100828A5 (enExample) | ||
| FI3371316T3 (fi) | Rokotteita hepatiitti b -virusta vastaan | |
| Schermuly et al. | In vitro model for lytic replication, latency, and transformation of an oncogenic alphaherpesvirus | |
| Liu et al. | Promising cytomegalovirus-based vaccine vector induces robust CD8+ T-cell response | |
| Dubensky Jr et al. | Delivery systems for gene-based vaccines | |
| JP2019531745A5 (enExample) | ||
| JP2019502371A5 (enExample) | ||
| Full et al. | T cells engineered with a cytomegalovirus-specific chimeric immunoreceptor | |
| Souquette et al. | Past life and future effects—how heterologous infections alter immunity to influenza viruses | |
| Pourchet et al. | CD8+ T-cell immune evasion enables oncolytic virus immunotherapy | |
| Khan et al. | Identification of cytomegalovirus-specific cytotoxic T lymphocytes in vitro is greatly enhanced by the use of recombinant virus lacking the US2 to US11 region or modified vaccinia virus Ankara expressing individual viral genes | |
| Abdelaziz et al. | Development of a human cytomegalovirus (HCMV)-based therapeutic cancer vaccine uncovers a previously unsuspected viral block of MHC class I antigen presentation |